In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor blocker is crucial after percutaneous coronary intervention (PCI) to prevent cardiovascular events and in-stent thrombosis.
• Newer P2Y12 antagonists offer improved platelet inhibition but introduce complexities in switching regimens.
• Current clinical practice lacks evidence-based guidelines for transitioning between P2Y12 inhibitors.

Observation:

• Two cases of ST-elevation myocardial infarction (STEMI) patients who developed in-stent thrombosis shortly after switching from ticagrelor to clopidogrel (300 mg loading dose) were observed.
• In-stent thrombosis occurred approximately 48 hours post-switch in both instances, despite initial successful stent placement.
• These events highlight the potential for suboptimal platelet inhibition during the transition period.

Findings:

• The observed cases suggest that a 300 mg clopidogrel loading dose may be insufficient when switching from ticagrelor, leading to a prothrombotic state.
• Suboptimal platelet inhibition following this specific medication switch can have severe clinical consequences, including recurrent ischemic events.
• The study underscores the critical need for specific dosing strategies when transitioning between potent P2Y12 receptor blockers.

Implications:

• The findings emphasize the urgent need for prospective, adequately powered clinical trials to investigate optimal switching strategies between ticagrelor and clopidogrel.
• Establishing evidence-based guidelines for P2Y12 inhibitor switching is essential to minimize the risk of in-stent thrombosis and improve patient outcomes.
• Clinicians should exercise caution when managing patients transitioning between different P2Y12 antagonists, considering the potential for inadequate platelet aggregation inhibition.